TumorOut (Innovative mRNA vaccine against lung cancer)
Innovative platform of targeted polymeric nanoparticles for efficient personalized therapy against lung cancer
Gobierno de España
Proyecto consorcio europeo
01/01/2023 a 31/12/2025
This is a TRANSCAN3 (ERA-NET Cofund) project that the involves the coordinated activities of 6 european research centres coordinated by IQS to develop a novel therapy to treat lung cancer (https://transcan.eu/output-results/funded-projects/tumorout.kl).
This project involves the coordinated activities of 6 european research centres coordinated by IQS to develop a novel therapy to treat lung cancer. Non-small cell lung cancer (NSCLC) treatment shows unprecedented improvement with immune checkpoint inhibitors (ICIs) but only a minority of NSCLC patients (25%) demonstrate long-term benefit. Our preliminary data and working hypothesis is that therapeutic mRNA vaccination, coupled with co-targeting of antigen-presenting cell (APC) immunosuppressive in a patient stratification strategy will sharply increase the number of patients who will benefit from ICIs.